BidaskClub cut shares of IDEXX Laboratories (NASDAQ:IDXX) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

A number of other brokerages also recently issued reports on IDXX. Zacks Investment Research raised IDEXX Laboratories from a hold rating to a buy rating and set a $184.00 price target on the stock in a report on Tuesday, October 24th. Stifel Nicolaus reaffirmed a buy rating and set a $185.00 price target on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Aegis reaffirmed a sell rating on shares of IDEXX Laboratories in a report on Friday, December 8th. Canaccord Genuity reaffirmed a buy rating and set a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. Finally, Bank of America raised IDEXX Laboratories from a neutral rating to a buy rating and set a $175.00 price target on the stock in a report on Wednesday, August 23rd. Three research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $173.67.

IDEXX Laboratories (IDXX) opened at $157.39 on Friday. The stock has a market capitalization of $13,730.00, a price-to-earnings ratio of 52.73, a PEG ratio of 2.37 and a beta of 0.42. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48. IDEXX Laboratories has a 1-year low of $113.92 and a 1-year high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. The firm had revenue of $492.00 million for the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The company’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.62 earnings per share. analysts predict that IDEXX Laboratories will post 3.24 EPS for the current year.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 54,000 shares of the stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total value of $8,171,280.00. Following the transaction, the chairman now owns 1,064,573 shares of the company’s stock, valued at $161,091,186.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Giovani Twigge sold 2,000 shares of the stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The disclosure for this sale can be found here. In the last three months, insiders sold 110,000 shares of company stock worth $16,686,200. 2.77% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its stake in shares of IDEXX Laboratories by 10.5% in the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock worth $1,146,142,000 after buying an additional 673,347 shares during the period. Advisors Capital Management LLC bought a new position in shares of IDEXX Laboratories in the third quarter worth about $262,000. Cipher Capital LP bought a new position in shares of IDEXX Laboratories in the second quarter worth about $2,284,000. American Century Companies Inc. raised its stake in shares of IDEXX Laboratories by 131.7% in the second quarter. American Century Companies Inc. now owns 480,978 shares of the company’s stock worth $77,639,000 after buying an additional 273,398 shares during the period. Finally, Koch Industries Inc. raised its stake in shares of IDEXX Laboratories by 44,533.1% in the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after buying an additional 1,396,113 shares during the period. 86.60% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/bidaskclub-lowers-idexx-laboratories-idxx-to-sell/1773674.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.